Related Experiment Video
Updated: Nov 9, 2025
Cell-free Biochemical Fluorometric Enzymatic Assay for High-throughput Measurement of Lipid Peroxidation in High Density Lipoprotein
Published on: October 12, 2017
Accurate and Efficient Lipoprotein Detection Based on the HCR-DNAzyme Platform
Hua-Jie Chen1, Yusi Hu2, Peiyu Yao3
1Engineering Research Center of Nano-Geomaterials of Ministry of Education, Faculty of Materials Science and Chemistry, China University of Geosciences, Wuhan 430074, P. R. China.
Insights
This study introduces a novel, rapid method for directly measuring high-density lipoprotein (HDL) and low-density lipoprotein (LDL) particle concentrations. This advance offers a more accurate way to assess cardiovascular disease risk by quantifying intact lipoprotein particles.
Area of Science:
- Biochemistry
- Molecular Diagnostics
- Cardiovascular Research
Background:
- Cardiovascular disease (CVD) is a leading global cause of mortality.
- Dyslipidemia, characterized by abnormal levels of high-density lipoprotein (HDL) and low-density lipoprotein (LDL), is a major risk factor for CVD.
- Current methods for assessing HDL and LDL particle levels are indirect, time-consuming, and labor-intensive, hindering accurate risk prediction.
Purpose of the Study:
- To develop an accurate and efficient method for the direct quantitative detection of intact high-density lipoprotein (HDL) and low-density lipoprotein (LDL) particles.
- To overcome the limitations of traditional indirect methods for lipoprotein analysis.
- To provide a tool for improved cardiovascular disease risk assessment and clinical management.
Main Methods:
- Development of an enzyme- and isolation-free detection platform.
- Utilized DNAzyme and hybridization chain reaction (HCR) for signal amplification.
- Directly measured the concentration of intact HDL and LDL particles.
Main Results:
- Achieved limits of detection of 10 mg/dL for HDL and 30 mg/dL for LDL.
- Demonstrated the method's capability for analyzing lipoprotein concentrations in clinical samples.
- The HCR-DNAzyme platform provides direct and accurate quantification of lipoprotein particles, not just cholesterol content.
Conclusions:
- The novel HCR-DNAzyme method offers a direct, accurate, and efficient approach for quantifying HDL and LDL particles.
- This platform shows significant potential for clinical applications in diagnosing and managing dyslipidemia and cardiovascular disease.
- The developed assay facilitates improved health management through precise lipoprotein analysis.
Abstract:
Cardiovascular disease is one of the main causes of death in the world, which is closely associated with dyslipidemia. Dyslipidaemia is usually manifested as a relatively higher level of low-density lipoprotein (LDL) and lower level of high-density lipoprotein (HDL). Thus, the quantitative detection of the LDL and HDL particles is of great importance to predict the risk of cardiovascular diseases. However, the traditional methods can only indirectly reflect the HDL/LDL particle concentrations by detecting the cholesterol or proteins in HDL/LDL particles and are always laborious and time-consuming. Thus, the accurate and efficient approach for the detection of intact HDL and LDL particles is still lacking so far. We developed an enzyme- and isolation-free method to measure the concentration of HDL and LDL based on DNAzyme and hybridization chain reaction (HCR)-based signal amplification. This method can be used to directly and accurately detect the concentration of "actual" HDL and LDL particles instead of the cholesterol in HDL and LDL, with limits of detection of 10 and 30 mg/dL, respectively, which also satisfied the lipoprotein analysis in clinical samples. Therefore, this HCR-DNAzyme platform has great potential in clinical applications and health management.
